长江商报消息 ●长江商报记者 潘瑞冬 小核酸药物赛道再添重磅国际合作。 2月23日晚间，前沿生物（688221.SH）发布公告，公司已于2月16日与全球生物制药巨头葛兰素史克 （GSK）签署独家授权协议，将旗下两款小核酸（siRNA）在研产品的全球权益授予GSK。根据公告， 此次授权协议的交易总金额或超10亿美元。 资料显示，前沿生物聚焦小核酸新药研发及其他新药的早期研发，此次授权的两款产品中，一款候选药 物已进入新药临床试验申请（IND）阶段，另一款处于临床前阶段。 值得一提的是，随着营业收入的增长和期间费用降低，前沿生物的扣非净利润连续三年减亏，根据公司 2025年业绩预告，公司预计扣非净利润亏损约2.88亿—3.23亿元，减少亏损约431.12万—3931.12万元。 达成超10亿美元授权合作 前沿生物与GSK达成超10亿美元合作，两款siRNA药物授权全球开发。 在研发分工上，双方实现优势互补。前沿生物将负责两款产品的早期开发工作，具体包括推进其中一款 产品在中国的I期临床试验，以及完成另一款产品的IND支持性研究；GSK则凭借其全球成熟的临床开 发、监管申报及商业化能力，承接两款产品后续所有的全球研 ...

Group 1 - The U.S. Supreme Court ruled that the government's imposition of tariffs under the International Emergency Economic Powers Act is illegal, prompting China to evaluate the implications and call for the removal of unilateral tariffs [1][12][30] - The A-share market is expected to perform positively post-Spring Festival, with a focus on technology growth and cyclical resource sectors, including AI assets and commercial aerospace [2][19] - ST Jinglan announced a significant stock price increase of 86.90% over a short period, indicating potential risks for investors if the price continues to rise abnormally [3][21] Group 2 - The Chinese film market set a record for the Spring Festival with total box office revenue exceeding 56 billion yuan, indicating strong consumer demand and a shift towards quality content [5][23] - Many companies continued operations during the Spring Festival, showcasing the resilience and vitality of the Chinese economy [6][24] - The first batch of new stocks for the year includes a high-end audio company and a core supplier for global electric vehicle battery safety components, with expectations for increased market activity [8][25] Group 3 - Frontier Biotech signed a global rights agreement with GlaxoSmithKline for two siRNA products, marking a significant international collaboration in the small nucleic acid drug sector [9][26] - The A-share market is transitioning from expectation-driven trading to a focus on fundamental verification, influenced by tightening monetary policies in major economies [10][27] - International gold and silver prices have seen significant increases, with gold surpassing $5160 per ounce and silver exceeding $87 per ounce, driven by rising demand and geopolitical uncertainties [11][28][29] Group 4 - Consumer behavior during the Spring Festival indicates a trend towards rational spending, with families opting for convenience in food purchases rather than traditional cooking [13][31] - Five chief economists provided insights on strengthening the capital market's stability and growth, emphasizing the need for multi-faceted efforts [14][32] - The 2026 Spring Festival Gala showcased technological advancements, highlighting the integration of robotics and AI in entertainment [15][33] Group 5 - The commercial aerospace sector is experiencing heightened investment interest, with increasing single financing amounts and several companies moving towards IPOs [17][35] - AI applications are facing a critical test following significant promotional efforts during the Spring Festival, with major companies leveraging their platforms for user acquisition [16][34]

小核酸药物赛道再添重磅国际合作。 2月23日晚间，前沿生物（688221）公告，公司已于2月16日与跨国药巨头葛兰素史克（GSK）签署独家授权协议，将旗下两款小核酸（siRNA）在研产品 的全球权益授予GSK。 分工明确 权益清晰 根据公告，此次授权的两款产品中，一款候选药物已进入新药临床试验申请（IND）阶段，另一款处于临床前阶段。 根据协议，前沿生物将负责其中一款产品在中国的I期临床试验推进，以及另一款产品的IND支持性研究；GSK则将主导两款产品后续的全球临床开发、 注册申报及商业化工作。 根据协议，前沿生物将获得4000万美元首付款及1300万美元近期里程碑付款，并有望在后续开发、监管和商业化过程中获得最高9.5亿美元的里程碑付 款，交易总金额累计超过10亿美元。此外，前沿生物还将享有两款产品全球净销售额的分级特许权使用费。 前沿生物在公告中表示，此次合作不仅将为公司带来可观的现金流支持，助力核心研发投入与技术平台升级，也标志着其在小核酸药物领域的技术实力获 得国际认可。公司在此次合作中将借助GSK在全球临床开发与商业化方面的资源与经验，加速公司管线的国际化价值转化，并为后续推进产品商业化、拓 展全球 ...